CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

India's One of the Women Entrepreneur Led Biotechnology Company's New Biosimilar in U.S. Gains Access to Over 100 Million Lives

The has given modest returns of 4.41 per cent over the past year. However, it has declined by 11.93 per cent over the last three years.

DSIJ Intelligence-2 0 216 Article rating: 4.1

The has given modest returns of 4.41 per cent over the past year. However, it has declined by 11.93 per cent over the last three years. 

Kiran Mazumdar Shaw-Backed Pharma Company is Likely to Raise Funds by Way of Issue of Equity Shares

The company has been maintaining a healthy dividend payout of 18 per cent.

DSIJ Intelligence-1 0 526 Article rating: 3.7

The company has a market cap of Rs 39,728 crore where Kiran Mazumdar Shaw (promoter of the company) holds a 40.36 per cent stake in the company.

The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar

Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.

DSIJ Intelligence-2 0 220 Article rating: 5.0

Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.

Rs 65 Million Investment Sparks Interest in Renewable Energy Acquisition by Subsidiary of Biocon

Syngene International Limited has a market capitalization of over Rs 28,000 crore, a 1-year return of 3 per cent, a 3-year return of 25 per cent and a PE ratio of 60.

DSIJ Intelligence-1 0 855 Article rating: 4.3

Syngene International Limited has a market capitalization of over Rs 28,000 crore, a 1-year return of 3 per cent, a 3-year return of 25 per cent and a PE ratio of 60.

Low PE & High ROE Stock: This bio-pharma company signs commercialization agreement with Juno Pharmaceuticals in Canada!

The shares of the company have a PE of 11.03x and an ROE of 31.94 per cent with multibagger returns of 375 per cent in a decade.

DSIJ Intelligence-1 0 4860 Article rating: 3.3

The shares of the company have a PE of 11.03x and an ROE of 31.94 per cent with multibagger returns of 375 per cent in a decade.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR